Author/Editor		Mavri, Alenka
Title		Povezava med metabolnim sindromom, inhibitorjem aktivatorja plazminogena (PAI-1) in aterosklerozo
Translated title		Metabolic syndrome, plasminogen activator inhibitor (PAI-1) and atherosclerosis
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 74, št. 6
Publication year		2005
Volume		str. 375-9
Language		slo
Abstract		Background. Metabolic syndrome is associated with high cardiovascular morbidity and mortality and its increasing prevalence is becoming one of the major health problems. Atherothrombotic process is accelerated in the metabolic syndrome and this is attributed to metabolic abnormalities, hypofibrinolysis due to increased plasma PAI-1 levels, and inflammation. Proinflammatory cytokines, particularly tumour necrosis factor-a may have an important role in PAI-1 overexpresion in the adipose tissue. PAI-1 might be involved in the etiopathogenesis of obesity and insulin resistance. Conclusions. To understand a complex interplay between metabolic syndrome, PAi-1 and atherosclerosis further studies are needed.
Summary		Izhodišča. Prevalenca metabolnega sindroma v razvitem svetu strmo narašča, kar je velik zdravstveni problem, saj metabolni sindrom spremlja visoka stopnja srčnožilne obolevnosti in umrljivosti. Na pospešen proces aterotromboze pri ljudeh z metabolnim sindromom vplivajo presnovne motnje, hipofibrinoliza zaradi zvečane ravni inhibitorja aktivatorja plazminogena (PAI-1) in kronično subklinično vnetje. Vnetni citokini, predvsem dejavnik tumorske nekroze-a, se vpletajo v uravnavanje tvorbe PAI-1 v maščevju. PAI-1 je lahko eden pomembnejših etiopatogenetskih dejavnikov tako za debelost kot tudi za neodzivnost na insulin. Zaključki. Za dokončno razjasnitev povezav med metabolnim sindromom, PAI-1 in aterosklerozo bodo potrebne še številne raziskave, predvsem intervencijske.
Descriptors		INSULIN RESISTANCE HYPERINSULINEMIA DIABETES MELLITUS, NON-INSULIN-DEPENDENT HYPERTENSION HYPERLIPIDEMIA PLASMINOGEN ACTIVATOR INHIBITOR 1 OBESITY ATHEROSCLEROSIS